• Jiazhou Li, Junlin Jiang, Chunxiang Jing, Wenjiang Zheng, and Huashan Pan.
• School of sport and health of Guangzhou University of Chinese Medicine.
• Medicine (Baltimore). 2020 Oct 30; 99 (44): e22917.

BackgroundChinese medicine Sangbaipi decoction is extensively applied to the therapy of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in China. However, owing to the low quality, small sample size, and methodological heterogeneity of these studies, this conclusion is not convincing. Consequently, it is necessary to systematically evaluate the clinical efficacy and safety of Sangbaipi Decoction in the treatment of AECOPD patients, and provide high-quality evidence for its clinical application.MethodsWe will follow the preferred reporting items for systematic review and meta-analysis (PRISMA) for reporting the results of the review in this study. We will utilize the Review Manage software V5.3.0 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) to assess the risk of bias and visualize the results. We will use Stata software (version 15.0, StataCorp, College Station, TX) to perform the meta-analysis.Ethics And DisseminationThis study is a systematic review and meta-analysis protocol of Sangbaipi decoction on AECOPD, participants were not recruited and data were not collected from participants, so ethical ratification is not required.ResultsThis study will provide high-quality synthesis of the effectiveness and safety of Sangbaipi decoction for AECOPD. Upon completion, the results will be submitted to a peer-reviewed journal.ConclusionThe efficacy and safety assessment of Sangbaipi decoction for AECOPD will be supported by this protocol.Registration NumberPROSPERO CRD 42019138405.

17 keywords...

hide…